Should I buy or sell CareDx stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for CareDx in the last twelve months. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" CDNA shares. View CDNA analyst ratings or view top-rated stocks .

What is CareDx's stock price target for 2024?

4 analysts have issued 1-year price objectives for CareDx's shares. Their CDNA share price targets range from $12.00 to $15.00. On average, they expect the company's share price to reach $13.50 in the next twelve months. This suggests a possible upside of 65.2% from the stock's current price. View analysts price targets for CDNA or view top-rated stocks among Wall Street analysts .

How have CDNA shares performed in 2024?

CareDx's stock was trading at $12.00 at the beginning of the year. Since then, CDNA shares have decreased by 31.9% and is now trading at $8.17. View the best growth stocks for 2024 here .

When is CareDx's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024. View our CDNA earnings forecast .

How were CareDx's earnings last quarter?

CareDx, Inc (NASDAQ:CDNA) issued its earnings results on Wednesday, February, 28th. The company reported ($2.21) EPS for the quarter, missing analysts' consensus estimates of ($0.24) by $1.97. The firm had revenue of $65.57 million for the quarter, compared to the consensus estimate of $63.66 million. CareDx had a negative net margin of 67.88% and a negative trailing twelve-month return on equity of 51.40%. The company's quarterly revenue was down 20.4% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.34) EPS.

What ETFs hold CareDx's stock?

ETFs with the largest weight of CareDx (NASDAQ:CDNA) stock in their portfolio include ARK Genomic Revolution ETF (ARKG) , Jacob Forward ETF (JFWD) , ROBO Global Healthcare Technology and Innovation ETF (HTEC) and Global X Genomics & Biotechnology ETF (GNOM) . First Trust Nasdaq Lux Digital Health Solutions ETF (EKG) .

What guidance has CareDx issued on next quarter's earnings?

CareDx updated its FY 2024 earnings guidance on Wednesday, February, 28th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $260.0 million-$274.0 million, compared to the consensus revenue estimate of $260.6 million.

What other stocks do shareholders of CareDx own?

Based on aggregate information from My MarketBeat watchlists, some companies that other CareDx investors own include Block (SQ) , Roku (ROKU) , Exact Sciences (EXAS) , NVIDIA (NVDA) , Advanced Micro Devices (AMD) , Tesla (TSLA) , Enphase Energy (ENPH) , Johnson & Johnson (JNJ) , Activision Blizzard (ATVI) and Alibaba Group (BABA) .

Who are CareDx's major shareholders?

CareDx's stock is owned by a number of institutional and retail investors. Top institutional investors include Los Angeles Capital Management LLC (0.50%). Insiders that own company stock include Ankur Dhingra , George Bickerstaff , Grace Colon, Michael Goldberg , Paul Adler , Peter Maag , Ralph Snyderman , Reginald Seeto , Sasha King , Thomas A Thomas and William A Hagstrom . View institutional ownership trends .

How do I buy shares of CareDx?

Shares of CDNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:CDNA

CareDx (CDNA) Stock Price, News & Analysis

→ Biden’s $374B Giveaway Into This Sector (From DTI) (Ad)

Free CDNA Stock Alerts

$8.16

-0.12 (-1.45%)

(As of 03:33 PM ET)

Compare

Today's Range: $8.10
▼
$8.50
50-Day Range: $7.85
▼
$12.08
52-Week Range: $4.80
▼
$12.93

Volume: 306,051 shs
Average Volume: 911,135 shs
Market Capitalization: $422.52 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $13.50

Get CareDx alerts:

CareDx MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.50 Rating Score
Upside/Downside: 65.2% Upside
$13.50 Price Target
Short Interest: Bearish
10.48% of Float Sold Short
Dividend Strength: N/A
Sustainability: -0.66
Upright™ Environmental Score
News Sentiment: 0.32
Based on 4 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($1.59) to ($1.17) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.11 out of 5 stars

Medical Sector

330th out of 914 stocks

Medical Laboratories Industry

10th out of 20 stocks

3.3

Analyst's Opinion

Consensus Rating
CareDx has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 2 buy ratings, 2 hold ratings, and no sell ratings.
Amount of Analyst Coverage
CareDx has only been the subject of 1 research reports in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
10.48% of the float of CareDx has been sold short.
Short Interest Ratio / Days to Cover
CareDx has a short interest ratio ("days to cover") of 5.5.
Change versus previous month
Short interest in CareDx has recently increased by 18.81%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
CareDx does not currently pay a dividend.
Dividend Growth
CareDx does not have a long track record of dividend growth.

4.2

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
CareDx has received a 61.52% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "DNA sequencers", "Genomics analysis tools", and "Patient flow management systems" products. See details.
Environmental Sustainability
The Environmental Impact score for CareDx is -0.66.

2.4

News and Social Media Coverage

News Sentiment
CareDx has a news sentiment score of 0.32. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.49 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 4 news articles for CareDx this week, compared to 3 articles on an average week.
Search Interest
Only 1 people have searched for CDNA on MarketBeat in the last 30 days. This is a decrease of -83% compared to the previous 30 days.
MarketBeat Follows
4 people have added CareDx to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, CareDx insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 4.20% of the stock of CareDx is held by insiders.

0.6

Earnings and Valuation

Earnings Growth
Earnings for CareDx are expected to grow in the coming year, from ($1.59) to ($1.17) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of CareDx is -2.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of CareDx is -2.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
CareDx has a P/B Ratio of 1.69. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad DTI

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story

About CareDx Stock (NASDAQ:CDNA)

CareDx, Inc. engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a surveillance solution that monitors the level of engraftment and persistence of allogeneic cells for patients who have received cell therapy transplants; and XynQAPI cloud-based transplant quality management software, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.

CDNA Stock Price History

30 days | 90 days | 365 days | Advanced Chart

CDNA Stock News Headlines

April 18, 2024 | investing.com

CareDx names John W. Hanna as new President and CEO

April 16, 2024 | businesswire.com

CareDx Appoints John W. Hanna as its New President and Chief Executive Officer

April 18, 2024 | Weiss Ratings (Ad)

Nvidia Has a BIG Problem — Here’s Who Benefits MOST

#1 AI Stock for 2024 Revealed In "AI Town Hall" This AI company just signed a deal with NVIDIA that went unreported by the media. Find out how you can get in on what is being dubbed 'the #1 AI stock for 2024 to buy now'

April 9, 2024 | finance.yahoo.com

CareDx and Collaborators Present Latest Cardiothoracic Advancements at the 2024 International Society for Heart and Lung Transplantation Meeting

April 9, 2024 | businesswire.com

CareDx and Collaborators Present Latest Cardiothoracic Advancements at the 2024 International Society for Heart and Lung Transplantation Meeting

March 26, 2024 | msn.com

Replimune Group announces CEO transition

March 16, 2024 | finance.yahoo.com

CDNA Apr 2024 10.000 put

March 16, 2024 | finance.yahoo.com

CDNA Apr 2024 2.500 call

April 18, 2024 | Weiss Ratings (Ad)

Nvidia Has a BIG Problem — Here’s Who Benefits MOST

March 14, 2024 | msn.com

UroGen Pharma reports mixed Q4 results; initiates FY24 outlook

March 11, 2024 | businesswire.com

CareDx Appoints Bryan Riggsbee to Its Board of Directors

March 6, 2024 | markets.businessinsider.com

CareDx Hold Rating: Balancing Modest Growth Prospects with Operational Uncertainties

March 4, 2024 | finance.yahoo.com

CDNA Mar 2024 17.500 call

March 1, 2024 | finance.yahoo.com

CareDx Full Year 2023 Earnings: EPS Misses Expectations

February 29, 2024 | finance.yahoo.com

CareDx, Inc (NASDAQ:CDNA) Q4 2023 Earnings Call Transcript

February 28, 2024 | msn.com

CareDx Non-GAAP EPS of -$0.17 beats by $0.10, revenue of $65.6M beats by $1.54M

February 28, 2024 | finance.yahoo.com

CareDx Announces Fourth Quarter and Full Year 2023 Financial Results

February 28, 2024 | finance.yahoo.com

CareDx Inc (CDNA) Surpasses Revenue Expectations Despite Net Loss Expansion in 2023

February 27, 2024 | finance.yahoo.com

CareDx to Participate in the Raymond James & Associates’ 45th Annual Institutional Investors Conference

February 27, 2024 | benzinga.com

Earnings Outlook For CareDx

February 27, 2024 | businesswire.com

CareDx to Participate in the Raymond James & Associates' 45th Annual Institutional Investors Conference

February 22, 2024 | benzinga.com

CareDx Stock (NASDAQ:CDNA), Short Interest Report

February 21, 2024 | finance.yahoo.com

CareDx to Report Fourth Quarter and Full Year 2023 Financial Results

February 21, 2024 | businesswire.com

CareDx to Report Fourth Quarter and Full Year 2023 Financial Results

February 21, 2024 | finance.yahoo.com

CareDx Showcases Digital Solutions and Pipeline in Cellular Transplant and Therapy Monitoring at the 2024 Tandem Meetings

February 21, 2024 | businesswire.com

CareDx Showcases Digital Solutions and Pipeline in Cellular Transplant and Therapy Monitoring at the 2024 Tandem Meetings

February 17, 2024 | finance.yahoo.com

CDNA Mar 2024 7.500 put

See More Headlines

Receive CDNA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CareDx and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/28/2024
Today: 4/18/2024
Next Earnings (Estimated): 5/08/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Medical laboratories
Sub-Industry: N/A
Current Symbol: NASDAQ:CDNA
CUSIP: N/A
CIK: 1217234
Web: www.caredxinc.com
Phone: (415) 287-2300
Fax: 415-287-2450
Employees: 635
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $13.50
High Stock Price Target: $15.00
Low Stock Price Target: $12.00
Potential Upside/Downside: +65.4%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.50
Research Coverage: 4 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($3.54)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-190,280,000.00
Net Margins: -67.88%
Pretax Margin: -67.83%
Return on Equity: -51.40%
Return on Assets: -37.85%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 4.02
Quick Ratio: 3.77

Sales & Book Value

Annual Sales: $280.32 million
Price / Sales: 1.51
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $4.83 per share
Price / Book: 1.69

Miscellaneous

Outstanding Shares: 51,780,000
Free Float: 49,604,000
Market Cap: $422.52 million
Optionable: Optionable
Beta: 1.42

20 Stocks to Sell Now

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

Mr. Abhishek Jain (Age 47)
CFO & Principal Accounting Officer
Comp: $425.58k
Dr. Peter Maag Ph.D. (Age 57)
Executive Director
Comp: $43.23k
Mr. Alexander L. Johnson (Age 50)
President of Patient & Testing Services
Comp: $547.43k
Ms. Marica Grskovic Ph.D.
Chief Operating Officer
Dr. Robert N. Woodward Ph.D.
Chief Scientific Officer
Mr. GS Jha
Senior VP, Chief Information Officer & Chief Information Security Officer
Mr. Ian Cooney
Vice President of Investor Relations
Jeffrey A. Novack
General Counsel
Ms. Stacey Follon
Senior VP & Head of Human Resources
Mr. Kashif Rathore
Chief of Patient & Digital Solutions

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

CDNA Stock Analysis - Frequently Asked Questions

Should I buy or sell CareDx stock right now?: 4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for CareDx in the last twelve months. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" CDNA shares.
View CDNA analyst ratings or view top-rated stocks.
What is CareDx's stock price target for 2024?: 4 analysts have issued 1-year price objectives for CareDx's shares. Their CDNA share price targets range from $12.00 to $15.00. On average, they expect the company's share price to reach $13.50 in the next twelve months. This suggests a possible upside of 65.2% from the stock's current price.
View analysts price targets for CDNA or view top-rated stocks among Wall Street analysts.
How have CDNA shares performed in 2024?: CareDx's stock was trading at $12.00 at the beginning of the year. Since then, CDNA shares have decreased by 31.9% and is now trading at $8.17.
View the best growth stocks for 2024 here.
When is CareDx's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024.
View our CDNA earnings forecast.
How were CareDx's earnings last quarter?: CareDx, Inc (NASDAQ:CDNA) issued its earnings results on Wednesday, February, 28th. The company reported ($2.21) EPS for the quarter, missing analysts' consensus estimates of ($0.24) by $1.97. The firm had revenue of $65.57 million for the quarter, compared to the consensus estimate of $63.66 million. CareDx had a negative net margin of 67.88% and a negative trailing twelve-month return on equity of 51.40%. The company's quarterly revenue was down 20.4% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.34) EPS.
What ETFs hold CareDx's stock?: ETFs with the largest weight of CareDx (NASDAQ:CDNA) stock in their portfolio include ARK Genomic Revolution ETF (ARKG), Jacob Forward ETF (JFWD), ROBO Global Healthcare Technology and Innovation ETF (HTEC) and Global X Genomics & Biotechnology ETF (GNOM).First Trust Nasdaq Lux Digital Health Solutions ETF (EKG).

What guidance has CareDx issued on next quarter's earnings?: CareDx updated its FY 2024 earnings guidance on Wednesday, February, 28th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $260.0 million-$274.0 million, compared to the consensus revenue estimate of $260.6 million.
What other stocks do shareholders of CareDx own?: Based on aggregate information from My MarketBeat watchlists, some companies that other CareDx investors own include Block (SQ), Roku (ROKU), Exact Sciences (EXAS), NVIDIA (NVDA), Advanced Micro Devices (AMD), Tesla (TSLA), Enphase Energy (ENPH), Johnson & Johnson (JNJ), Activision Blizzard (ATVI) and Alibaba Group (BABA).
Who are CareDx's major shareholders?: CareDx's stock is owned by a number of institutional and retail investors. Top institutional investors include Los Angeles Capital Management LLC (0.50%). Insiders that own company stock include Ankur Dhingra, George Bickerstaff, Grace Colon, Michael Goldberg, Paul Adler, Peter Maag, Ralph Snyderman, Reginald Seeto, Sasha King, Thomas A Thomas and William A Hagstrom.
View institutional ownership trends.
How do I buy shares of CareDx?: Shares of CDNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CDNA) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial